Navigation Links
MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
Date:7/15/2010

operties, such as Fc receptor binding and extended half-life.  This functionality can be further expanded with the inclusion of MacroGenics' proprietary Fc domain portfolio.  MacroGenics has established and continues to expand a patent estate around the DART technology.

About MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases.  Since its founding in 2000, the company has built a fully-integrated set of capabilities in monoclonal antibody product development.  The company's product development efforts leverage three proprietary technology platforms: (1) cancer stem-like cells; (2) DART, which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions.  These powerful sets of capabilities and technology platforms have enabled MacroGenics to build a proprietary pipeline of innovative product candidates.  The company's lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune diseases.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projecte
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MacroGenics Raises $25M in Series D-2 Financing
2. MacroGenics Appoints New Vice President of Business Development
3. Paulo F. Costa Joins MacroGenics Board of Directors
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
10. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
11. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Not even geckos and spiders can sit upside down forever. ... have demonstrated this in an article just published in ... industrial benefit. , Geckos and spiders that seem to be ... have fascinated researchers worldwide for many years. We will soon ... same way as the gecko,s foot. But the fact is, ...
(Date:7/10/2014)... University of Illinois at Urbana-Champaign provides new insights ... spin and heat at the nanoscale, and addresses ... data storage and information processing. , "Electrons ... In a typical charge current, electrons, spin-angular-momentum is ... David Cahill, a professor of materials science and ...
(Date:1/15/2014)... akin to assembling a club sandwich at the ... researchers have succeeded in crafting a uniform, multi-walled ... foam commonly used in upholstered furniture and other ... polyurethane foam was reduced 35 percent compared with ...
(Date:1/15/2014)... Ill. , Jan. 15, 2014  Bill Jacobs Automotive, a ... , is teaming up with the Heartland Blood Center and ... blood drive. The drive takes place Saturday, Jan. 18 at ... - 2 p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  ...
Breaking Biology Technology:Even geckos can lose their grip 2University of Illinois study advances limits for ultrafast nano-devices 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Join the Bill Jacobs Auto blood drive and receive a free oil change 2
... of Convertible Preferred Stock -, DALLAS, Jan. ... announced today that it has executed agreements,for $2.7 ... into agreements,with institutional and accredited investors to purchase ... the Company,s Series A Convertible,Preferred Stock. This equity ...
... Healionics Corporation, a,provider of tissue regeneration and ... it has raised $1.7 million,in a Series A ... Carl Lombardi, former CEO of SpaceLabs Medical and ... & Rejuvenation Center., "We are pleased to ...
... in cash at year end; no equity financings expected ... disease programs to continue in,2008; latest data for all ... - Expansion of research and development investment ... lysosomal diseases in 2008, CRANBURY, N.J., Jan. 29 ...
Cached Biology Technology:Access Pharmaceuticals Announces $2.7 Million New Equity 2Access Pharmaceuticals Announces $2.7 Million New Equity 3Healionics Corporation Completes Series A Financing 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14
(Date:7/11/2014)... have explored two different ways that allow unprecedented ... the formation of oxygen molecules in photosynthesis. The ... journal Nature Communications . , "The new ... for water oxidation, which are key components for ... of solar energy in fuels like hydrogen, ethanol ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2'Tailored' water -- the latest in lawn care 2
... non-native mussels in the Great Lakes has caused ... two of the planet,s largest freshwater lakes, according ... The blitzkrieg advance of two closely related species ... of their life-supporting algae, resulting in a remarkable ...
... 2011 A natural hormone known to inhibit aging can ... researchers have demonstrated. Scientists led by Dr. Makoto Kuro-o, ... hormone Klotho suppressed both renal fibrosis a common complication ... The findings are available online in the Journal of ...
... warming may be the greatest challenge of the present generation. ... the average citizen often wonders what he or she can ... FROM GERMANY,S SUCCESS IN HARNESSING CLEAN ENERGY" (Prometheus Books, $19) ... in the making veteran science and technology journalist Bob ...
Cached Biology News:Invasive mussels causing massive ecological changes in Great Lakes 2Invasive mussels causing massive ecological changes in Great Lakes 3Anti-aging hormone Klotho inhibits renal fibrosis, cancer growth 2Switching to solar 2